For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
ApexOnco Front Page
Recent articles
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
First-in-human trial initiations feature Interius, Umoja and Vironexis.
BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.
NVL-330 features among the latest crop of industry projects newly into human trials.
Western data on EO-3021 fail to live up to the billing of a Chinese trial.
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
More bad news for CD47 as response rates in Aspen-06 wane, and the company turns to a subgroup.
